MDM2-Dependent Downregulation of p21 and hnRNP K Provides a Switch between Apoptosis and Growth Arrest Induced by Pharmacologically Activated p53 (DOI:10.1016/j.ccr.2009.01.019);MDM2-Dependent Downregulation of p21 and hnRNP K Provides a Switch between Apoptosis and Growth Arrest Induced by Pharmacologically Activated p53

Cancer Cell

Volumn 15, Issue 3, 2009, Pages 171-183

  Enge, Martin ^a   Bao, Wenjie ^a   Hedström, Elisabeth ^a   Jackson, Stephen P ^b   Moumen, Abdeladim ^b,c   Selivanova, Galina ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

CELLCYCLE

Indexed keywords

HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN K; PROTEIN MDM2; PROTEIN P21; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 60649103811     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2009.06.012     Document Type: Erratum

References (38)

1. Ashburner M., Ball C.A., Blake J.A., Botstein D., Butler H., Cherry J.M., Davis A.P., Dolinski K., Dwight S.S., Eppig J.T., et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 25 (2000) 25-29
2. Baptiste-Okoh N., Barsotti A.M., and Prives C. Caspase 2 is both required for p53-mediated apoptosis and downregulated by p53 in a p21-dependent manner. Cell Cycle 7 (2008) 1133-1138
3. Boyd K.E., Wells J., Gutman J., Bartley S.M., and Farnham P.J. c-Myc target gene specificity is determined by a post-DNAbinding mechanism. Proc. Natl. Acad. Sci. USA 95 (1998) 13887-13892
4. Brummelkamp T.R., Fabius A.W., Mullenders J., Madiredjo M., Velds A., Kerkhoven R.M., Bernards R., and Beijersbergen R.L. An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat. Chem. Biol. 2 (2006) 202-206
5. Bunz F., Dutriaux A., Lengauer C., Waldman T., Zhou S., Brown J.P., Sedivy J.M., Kinzler K.W., and Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282 (1998) 1497-1501
6. D'Orazi G., Cecchinelli B., Bruno T., Manni I., Higashimoto Y., Saito S., Gostissa M., Coen S., Marchetti A., Del Sal G., et al. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat. Cell Biol. 4 (2002) 11-19
7. Gartel A.L., and Tyner A.L. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol. Cancer Ther. 1 (2002) 639-649
8. Issaeva N., Bozko P., Enge M., Protopopova M., Verhoef L.G., Masucci M., Pramanik A., and Selivanova G. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. 10 (2004) 1321-1328
9. Jin Y., Lee H., Zeng S.X., Dai M.S., and Lu H. MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation. EMBO J. 22 (2003) 6365-6377
10. Kanehisa M., and Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28 (2000) 27-30
11. Kitagawa M., Aonuma M., Lee S.H., Fukutake S., and McCormick F. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines. Oncogene 27 (2008) 5303-5314
12. Lai Z., Yang T., Kim Y.B., Sielecki T.M., Diamond M.A., Strack P., Rolfe M., Caligiuri M., Benfield P.A., Auger K.R., et al. Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors. Proc. Natl. Acad. Sci. USA 99 (2002) 14734-14739
13. Lain S., Hollick J.J., Campbell J., Staples O.D., Higgins M., Aoubala M., McCarthy A., Appleyard V., Murray K.E., Baker L., et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 13 (2008) 454-463
14. Marshall O.J. PerlPrimer: cross-platform, graphical primer design for standard, bisulphite and real-time PCR. Bioinformatics 20 (2004) 2471-2472
15. Moreno C.S., Matyunina L., Dickerson E.B., Schubert N., Bowen N.J., Logani S., Benigno B.B., and McDonald J.F. Evidence that p53-mediated cell-cycle-arrest inhibits chemotherapeutic treatment of ovarian carcinomas. PLoS ONE 2 (2007) e441
16. Moumen A., Masterson P., O'Connor M.J., and Jackson S.P. hnRNP K: an HDM2 target and transcriptional coactivator of p53 in response to DNA damage. Cell 123 (2005) 1065-1078
17. Olivier M., Eeles R., Hollstein M., Khan M.A., Harris C.C., and Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum. Mutat. 19 (2002) 607-614
18. Riley T., Sontag E., Chen P., and Levine A. Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell Biol. 9 (2008) 402-412
19. Samuels-Lev Y., O'Connor D.J., Bergamaschi D., Trigiante G., Hsieh J.K., Zhong S., Campargue I., Naumovski L., Crook T., and Lu X. ASPP proteins specifically stimulate the apoptotic function of p53. Mol. Cell 8 (2001) 781-794
20. Shaked H., Shiff I., Kott-Gutkowski M., Siegfried Z., Haupt Y., and Simon I. Chromatin immunoprecipitation-on-chip reveals stress-dependent p53 occupancy in primary normal cells but not in established cell lines. Cancer Res. 68 (2008) 9671-9677
21. Smyth G.K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3 (2004) Article3
22. Staib F., Robles A.I., Varticovski L., Wang X.W., Zeeberg B.R., Sirotin M., Zhurkin V.B., Hofseth L.J., Hussain S.P., Weinstein J.N., et al. The p53 tumor suppressor network is a key responder to microenvironmental components of chronic inflammatory stress. Cancer Res. 65 (2005) 10255-10264
23. Steinman R.A., and Johnson D.E. p21WAF1 prevents down-modulation of the apoptotic inhibitor protein c-IAP1 and inhibits leukemic apoptosis. Mol. Med. 6 (2000) 736-749
24. Suzuki A., Tsutomi Y., Akahane K., Araki T., and Miura M. Resistance to Fas-mediated apoptosis: activation of caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP. Oncogene 17 (1998) 931-939
25. Sykes S.M., Mellert H.S., Holbert M.A., Li K., Marmorstein R., Lane W.S., and McMahon S.B. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol. Cell 24 (2006) 841-851
26. Tang Y., Luo J., Zhang W., and Gu W. Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol. Cell 24 (2006) 827-839
27. Tian L., Greenberg S.A., Kong S.W., Altschuler J., Kohane I.S., and Park P.J. Discovering statistically significant pathways in expression profiling studies. Proc. Natl. Acad. Sci. USA 102 (2005) 13544-13549
28. Tovar C., Rosinski J., Filipovic Z., Higgins B., Kolinsky K., Hilton H., Zhao X., Vu B.T., Qing W., Packman K., et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc. Natl. Acad. Sci. USA 103 (2006) 1888-1893
29. Tusher V.G., Tibshirani R., and Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. USA 98 (2001) 5116-5121
30. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303 (2004) 844-848
31. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network. Nature 408 (2000) 307-310
32. Vousden K.H., and Lu X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2 (2002) 594-604
33. Wade M., Wong E.T., Tang M., Stommel J.M., and Wahl G.M. Hdmx modulates the outcome of p53 activation in human tumor cells. J. Biol. Chem. 281 (2006) 33036-33044
34. Wei C.L., Wu Q., Vega V.B., Chiu K.P., Ng P., Zhang T., Shahab A., Yong H.C., Fu Y., Weng Z., et al. A global map of p53 transcription-factor binding sites in the human genome. Cell 124 (2006) 207-219
35. Wu Z., Irizarry R., Gentleman R., Martinez-Murillo F., and Spencer F. A model-based background adjustment for oligonucleotide expression arrays. J. Am. Stat. Assoc. 99 (2004) 909-917
36. Xu H., and el-Gewely M.R. P53-responsive genes and the potential for cancer diagnostics and therapeutics development. Biotechnol. Annu. Rev. 7 (2001) 131-164
37. Yang Y., Ludwig R.L., Jensen J.P., Pierre S.A., Medaglia M.V., Davydov I.V., Safiran Y.J., Oberoi P., Kenten J.H., Phillips A.C., et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 7 (2005) 547-559
38. Zhang Z., Wang H., Li M., Agrawal S., Chen X., and Zhang R. MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J. Biol. Chem. 279 (2004) 16000-16006